Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

This trial will be conducted in two parts: Part A and Part B. In Part A, pharmacokinetic (PK)
sampling will be conducted to identify the pediatric dose providing sugammadex exposure
similar to adults. For Part B participants, the efficacy of sugammadex (i.e. time to recovery
of the TOF ratio) will be assessed. Further, safety analyses will be conducted in both Parts
A and B. Following completion of Part A, an interim analysis (IA) of the PK and safety data
will be performed. Once the appropriate doses are confirmed and safety data is assessed for
the 2 doses of sugammadex, then Part B will commence.

Inclusion Criteria:

- Be categorized as American Society of Anesthesiologists (ASA) Physical Status Class 1,
2, or 3.

- Have a planned non-emergent surgical procedure or clinical situation (e.g.,
intubation) that requires moderate or deep NMB with either rocuronium or vecuronium.

- Have a planned surgical procedure or clinical situation that would allow objective
neuromuscular monitoring techniques to be applied with access to the arm for
neuromuscular transmission monitoring.

- Age between 2 to <17 years at Visit 2.

- If female, may participate if she is not pregnant, not breastfeeding, and at least one
of the following: 1) Not a woman of childbearing potential (WOCBP); or 2) A WOCBP who
agrees to follow the study contraceptive guidance during the treatment period and for
at least 7 days after the last dose of study treatment.

Exclusion Criteria:

- Has any clinically significant condition or situation (eg, anatomical malformation
that complicates intubation) other than the condition being studied that, in the
opinion of the investigator, would interfere with the trial evaluations or optimal
participation in the trial.

- Has a neuromuscular disorder that may affect NMB and/or trial assessments.

- Is dialysis-dependent or has (or is suspected of having) severe renal insufficiency
(defined as estimated glomerular filtration rate (eGFR) <30 ml/min).

- Has or is suspected of having a family or personal history of malignant hyperthermia.

- Has or is suspected of having an allergy to study treatments or its/their excipients,
to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used
during general anesthesia.

- Has received or is planned to receive toremifene and/or fusidic acid via IV
administration within 24 hours before or within 24 hours after administration of study
treatment.

- Has been previously treated with sugammadex or has participated in a sugammadex
clinical trial.

- Is currently participating in or has participated in an interventional clinical trial
with an investigational compound or device within 30 days of signing the informed
consent/assent for this current trial.